Cargando…
Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
AIMS: Addition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy. Fixed-dose combinations (FDC) improve medication adherence and facilitate risk factor control. We assessed prescriptio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234160/ https://www.ncbi.nlm.nih.gov/pubmed/35770230 http://dx.doi.org/10.3389/fcvm.2022.912785 |
_version_ | 1784735995970715648 |
---|---|
author | Katzmann, Julius L. Kieble, Marita Enners, Salka Böhm, Michael Mahfoud, Felix Laufs, Ulrich Schulz, Martin |
author_facet | Katzmann, Julius L. Kieble, Marita Enners, Salka Böhm, Michael Mahfoud, Felix Laufs, Ulrich Schulz, Martin |
author_sort | Katzmann, Julius L. |
collection | PubMed |
description | AIMS: Addition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy. Fixed-dose combinations (FDC) improve medication adherence and facilitate risk factor control. We assessed prescription trends of ezetimibe as monotherapy or FDC with statins. METHODS: Data from the German Institute for Drug Use Evaluation (DAPI) containing dispensing data of >80% of community pharmacies were analyzed. Prescriptions over time of lipid-lowering agents at the expense of the statutory health insurance (SHI) were extrapolated to all SHI-insured persons, representing approximately 88% of the total German population. Drug utilization was expressed as defined daily doses per 1,000 SHI-insured persons per day (DID). RESULTS: Of all lipid-lowering drug prescriptions in 2021, 91.2% were statin monotherapy. Ezetimibe was prescribed as monotherapy or FDC with statin in 4.4 and 2.9%, respectively. DID steadily increased for statin (69%) and ezetimibe (424%) monotherapies between 2012 and 2021. In contrast, statin-ezetimibe FDC prescriptions exhibited only a minor increase (29%). The proportion of statin-ezetimibe FDC among all statin prescriptions was stable over time at approximately 3%. FDC prescription rates by specialists were higher compared to general practitioners and varied considerably between geographic areas. CONCLUSION: Combination lipid-lowering therapy is prescribed to a minority of patients. Prescriptions of ezetimibe as monotherapy increased to a much greater extent than statin-ezetimibe FDC. Considering the low proportion of patients achieving their LDL-C target and improved adherence to FDC compared to separate pills, statin-ezetimibe FDC may be utilized to improve the management of dyslipidemia. |
format | Online Article Text |
id | pubmed-9234160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92341602022-06-28 Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 Katzmann, Julius L. Kieble, Marita Enners, Salka Böhm, Michael Mahfoud, Felix Laufs, Ulrich Schulz, Martin Front Cardiovasc Med Cardiovascular Medicine AIMS: Addition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy. Fixed-dose combinations (FDC) improve medication adherence and facilitate risk factor control. We assessed prescription trends of ezetimibe as monotherapy or FDC with statins. METHODS: Data from the German Institute for Drug Use Evaluation (DAPI) containing dispensing data of >80% of community pharmacies were analyzed. Prescriptions over time of lipid-lowering agents at the expense of the statutory health insurance (SHI) were extrapolated to all SHI-insured persons, representing approximately 88% of the total German population. Drug utilization was expressed as defined daily doses per 1,000 SHI-insured persons per day (DID). RESULTS: Of all lipid-lowering drug prescriptions in 2021, 91.2% were statin monotherapy. Ezetimibe was prescribed as monotherapy or FDC with statin in 4.4 and 2.9%, respectively. DID steadily increased for statin (69%) and ezetimibe (424%) monotherapies between 2012 and 2021. In contrast, statin-ezetimibe FDC prescriptions exhibited only a minor increase (29%). The proportion of statin-ezetimibe FDC among all statin prescriptions was stable over time at approximately 3%. FDC prescription rates by specialists were higher compared to general practitioners and varied considerably between geographic areas. CONCLUSION: Combination lipid-lowering therapy is prescribed to a minority of patients. Prescriptions of ezetimibe as monotherapy increased to a much greater extent than statin-ezetimibe FDC. Considering the low proportion of patients achieving their LDL-C target and improved adherence to FDC compared to separate pills, statin-ezetimibe FDC may be utilized to improve the management of dyslipidemia. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234160/ /pubmed/35770230 http://dx.doi.org/10.3389/fcvm.2022.912785 Text en Copyright © 2022 Katzmann, Kieble, Enners, Böhm, Mahfoud, Laufs and Schulz. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Katzmann, Julius L. Kieble, Marita Enners, Salka Böhm, Michael Mahfoud, Felix Laufs, Ulrich Schulz, Martin Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title_full | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title_fullStr | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title_full_unstemmed | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title_short | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 |
title_sort | trends in ezetimibe prescriptions as monotherapy or fixed-dose combination in germany 2012–2021 |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234160/ https://www.ncbi.nlm.nih.gov/pubmed/35770230 http://dx.doi.org/10.3389/fcvm.2022.912785 |
work_keys_str_mv | AT katzmannjuliusl trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT kieblemarita trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT ennerssalka trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT bohmmichael trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT mahfoudfelix trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT laufsulrich trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 AT schulzmartin trendsinezetimibeprescriptionsasmonotherapyorfixeddosecombinationingermany20122021 |